The present invention is directed to certain fused pyrimidines having a homo or hetero cyclopentyl, cyclohexyl or cycloheptyl ring as the pyrimidine fusion partner; having an amino benzyl or substituted amino benzyl group at the 4 position of the pyrimidine ring; and a 5:6 heterobicyclo ring with at least one N, O or S at the 2 position of the pyrimidine ring. These compounds are useful for treatment of cancer by inhibition of the p97 complex.
The one-pot reaction of valerolactone with nitriles in the presence of triflic anhydride affords 2,4-disubstituted pyrano[2,3-d]pyrimidines. Subsequent addition of methyl thiocyanate leads to 2,4-bis(methylthio)pyranopyrimidines which can easily be converted into the corresponding methylsulfonyl derivatives. The reaction of these derivatives with different nucleophiles produces a variety of substituted pyranopyrimidines.
FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
申请人:Cleave Biosciences, Inc.
公开号:EP3097092A1
公开(公告)日:2016-11-30
FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX
申请人:Cleave Biosciences, Inc.
公开号:EP3097092B1
公开(公告)日:2020-08-26
COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS
申请人:Wilson Dean M.
公开号:US20120040935A1
公开(公告)日:2012-02-16
The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.